Cargando…

Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations

[Image: see text] Nearly a century after its first description, configurationally stable axial chirality remains a rare feature in marketed drugs. In the development of the KRAS(G12C) inhibitor sotorasib (LUMAKRAS/LUMYKRAS), an axially chiral biaryl moiety proved a critical structural element in eng...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanman, Brian A., Parsons, Andrew T., Zech, Stephan G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583618/ https://www.ncbi.nlm.nih.gov/pubmed/36178208 http://dx.doi.org/10.1021/acs.accounts.2c00479

Ejemplares similares

CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
por: Zhang, Shannon S, et al.
Publicado: (2023)

Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer
por: Zhang, Shannon S, et al.
Publicado: (2021)

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS(G12C)-mutant cancer
por: Chiou, Li-Wen, et al.
Publicado: (2023)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
por: Koster, Kira-Lee, et al.
Publicado: (2022)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
por: Inno, Alessandro, et al.
Publicado: (2023)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report
por: Iska, Sindu, et al.
Publicado: (2023)

Remarkable Intracranial Response to Sotorasib in a Patient With KRAS(G12C)-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report
por: Yeh, Justin, et al.
Publicado: (2022)

Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2022)

Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS(G12C)-Mutant Non–Small-Cell Lung Cancer
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Modeling receptor flexibility in the structure-based design of KRAS(G12C) inhibitors
por: Zhu, Kai, et al.
Publicado: (2022)

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
por: Stites, Edward C., et al.
Publicado: (2018)

Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition
por: Huynh, Minh V., et al.
Publicado: (2022)

Correction to: Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Establishment of atropisomerism in 3-indolyl furanoids: a synthetic, experimental and theoretical perspective
por: Chatterjee, Sourav, et al.
Publicado: (2019)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
por: Okada, Kohei, et al.
Publicado: (2023)

Atropisomerism in the Pharmaceutically Relevant Realm
por: Basilaia, Mariami, et al.
Publicado: (2022)

Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS(G12C)
por: Mortier, Jérémie, et al.
Publicado: (2020)

BINOL-like atropisomeric chiral nanographene
por: Li, Shengtao, et al.
Publicado: (2023)

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
por: Dy, Grace K., et al.
Publicado: (2023)

Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report
por: Li, Ce, et al.
Publicado: (2022)

General Approach to the Synthesis of Prochiral Atropisomeric Biaryls
por: Kielar, Katarzyna, et al.
Publicado: (2011)

Unraveling the Pivotal Role of Atropisomerism for Cellular Internalization
por: Donohoe, Claire, et al.
Publicado: (2022)

Synthesis of Adagrasib (MRTX849), a Covalent KRAS(G12C) Inhibitor Drug for the Treatment of Cancer
por: Chen, Cheng-yi, et al.
Publicado: (2023)

Covalent inhibitor targets KRas(G12C): A new paradigm for drugging the undruggable and challenges ahead
por: Li, Hui-yu, et al.
Publicado: (2021)

Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance
por: Thatikonda, Venu, et al.
Publicado: (2023)

A Rare Event of Liver Dysfunction on Sotorasib and Management Strategy
por: Kinahan, Holly
Publicado: (2022)

Catalyst-Controlled Stereodivergent Synthesis of Atropisomeric Multiaxis Systems
por: Lotter, Dominik, et al.
Publicado: (2018)

Atropisomerism in Diarylamines: Structural Requirements and Mechanisms of Conformational Interconversion
por: Costil, Romain, et al.
Publicado: (2020)

Elucidating Atropisomerism in Nonplanar Porphyrins with Tunable Supramolecular Complexes
por: Norvaiša, Karolis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gj3plma9hbcr0uein27rn12a25